See the DrugPatentWatch profile for Delstrigo
Delstrigo, a single-tablet regimen for HIV-1 treatment, has a program that offers patients a free trial of the medication. This program allows eligible individuals to receive a 30-day supply of Delstrigo at no cost [1]. To qualify for the Delstrigo trial offer, patients must have commercial insurance and be starting their first prescription for Delstrigo [1]. The offer is not valid for patients using government-funded prescription programs, such as Medicare Part D, Medicare Advantage, Medicaid, or TRICARE [1].
What is Delstrigo used for?
Delstrigo is prescribed as a complete treatment regimen for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) and are living with HIV-1 infection [1]. It contains three antiretroviral medications: doravirine, lamivudine, and tenofovir disoproxil fumarate [1].
How does the Delstrigo trial offer work?
The Delstrigo trial offer provides a free 30-day supply of the medication. Patients can get a savings card from their doctor or by visiting the Delstrigo website to access this offer [1]. This program is intended to help patients begin treatment without an immediate financial barrier [1].
Who is eligible for the Delstrigo trial offer?
Eligibility for the Delstrigo trial offer is limited to patients starting their first prescription of Delstrigo who have commercial insurance [1]. Patients enrolled in federal or state healthcare programs are excluded from this particular offer [1].
Are there any restrictions on the Delstrigo trial offer?
Yes, the Delstrigo trial offer is restricted to patients with commercial insurance who are initiating Delstrigo treatment for the first time [1]. It cannot be combined with other offers, and it is not valid for individuals covered by government health insurance plans [1]. The offer also has an expiration date, and terms and conditions apply [1].
Where can I find more information about Delstrigo?
Further details about Delstrigo, including its uses, dosages, and the trial offer, can be found on the official Delstrigo website and through healthcare providers [1]. Information regarding HIV-1 treatment options and drug patents is available on sites like DrugPatentWatch.com [2].
Sources:
[1] Delstrigo.com
[2] DrugPatentWatch.com